Today: 9 June 2026
IMI plc starts £500 million buyback after strong 2025 results as shares slip
10 March 2026
1 min read

IMI plc starts £500 million buyback after strong 2025 results as shares slip

LONDON, March 9, 2026, 23:43 GMT

  • IMI kicked off the initial £250 million phase of its £500 million share buyback this Monday, appointing J.P. Morgan Securities to oversee the process. Shares bought back under the programme will be cancelled.
  • IMI is looking at a sixth consecutive year of mid-single-digit organic growth, with 2025 revenue up 4% and an adjusted operating margin landing at 20.0%.

IMI kicked off its initial £250 million share buyback on Monday, just days after the British engineering firm announced the £500 million plan alongside its annual results. J.P. Morgan Securities is handling the first phase, according to a regulatory filing, with the programme set to run until Dec. 31, 2026, at the latest.

This step lands now, putting some real action behind the buyback just as sentiment across markets sours. London’s FTSE 100 wrapped up Monday at a five-week low. IMI shares dropped 3.1%, even though net debt sits at 1.0 times EBITDA—right at the low end of the group’s target.

About 45% of the company’s revenue is now generated from higher-margin aftermarket business—service and spare parts after installation, according to the company. For 2026, it’s starting out with a larger Process Automation order book compared to last year.

Birmingham-based engineer IMI projected on Friday it’s heading for a sixth consecutive year of mid-single-digit organic revenue gains in 2026, and sees adjusted earnings per share coming in around 136p to 142p. Organic growth excludes impacts from currency fluctuations, acquisitions, or disposals.

Revenue landed at 2.304 billion pounds for 2025, up 4%, or 5% organically. Adjusted operating profit increased 6% to 460 million pounds, pushing margin out to 20.0%. Adjusted pretax profit was 442 million pounds. The board raised the full-year dividend 10% to 34.2 pence per share.

Automation took center stage. Process Automation revenue jumped 12% on an organic basis, with aftermarket orders in that segment climbing 11%. Demand linked to power, nuclear, and data-center projects gave the unit a boost. Industrial Automation, however, edged down 1% as global factory activity lost steam.

Chief Executive Roy Twite pointed to the strategy as “creating significant value for shareholders,” describing IMI as “well placed” to capture demand in energy, automation and healthcare. He linked the buyback plan to IMI’s capital discipline and strong cash flow. IMI plc

IMI’s move places it next to UK engineering rival Smiths Group, which kicked off a 1 billion-pound buyback back in November after it posted revenue gains.

The outlook’s complicated. IMI flagged that 2026 margin gains will be dented by higher cyber security costs, and the forecasts hinge on the £225 million Truflo Marine sale closing in mid-2026, pending regulatory and other green lights.

IMI has its next trading update scheduled for May 12.

Stock Market Today

  • Parabilis Medicines Boosts IPO to Potential $637 Million, Set to Break Biotech Records
    June 9, 2026, 10:57 AM EDT. Cancer biotech Parabilis Medicines has raised its initial public offering target to potentially $636.8 million, aiming to surpass the record set by Kailera Therapeutics' $625 million IPO. The Massachusetts-based company plans to offer over 33 million common shares at $17 to $19 each, primarily to fund phase 3 trials of zolucatetide for desmoid tumors, a rare type of benign connective tissue growth. Parabilis leverages innovative helicon peptide drugs targeting previously undruggable pathways, notably the Wnt/b-catenin signaling linked to cancer. The firm has secured substantial private funding, including a $305 million Series F round earlier this year. If successful, Parabilis will join other biotechs such as Kailera on the Nasdaq, marking a significant entry in the biotech IPO landscape.

Latest articles

Smart Logistics Jumps 159% Before Nasdaq Halt

Smart Logistics Jumps 159% Before Nasdaq Halt

9 June 2026
Smart Logistics Global soared 158.75% to $1.33 before a Nasdaq volatility pause, putting the stock above the $1 minimum bid-price needed for compliance after months below the threshold; the company must now close at or above $1 for 10 straight business days to avoid further Nasdaq action, with no new company news driving the surge.
Reddit Shares Pop After Wall Street Sees the Right Ad Signal

Reddit Shares Pop After Wall Street Sees the Right Ad Signal

9 June 2026
Reddit shares surged 6.6% to $182.44 after Cleveland Research and Piper Sandler cited stronger ad demand and raised revenue forecasts, with Cleveland noting 45% of advertisers beat ROI targets in Q2 and Reddit taking ad share from rivals, but risks remain around user growth, AI search traffic, and high valuation.
Autozi Shares Jump 400%, Filing Flags Risks for AZI

Autozi Shares Jump 400%, Filing Flags Risks for AZI

9 June 2026
Autozi Internet Technology shares soared over 400% to $5.69 in early Nasdaq trading after a 10-for-1 share consolidation slashed its share count to about 4.49 million, but the surge contrasts with a 63.1% revenue drop, 82.5% plunge in gross profit, and widened net loss, with the company warning of “substantial doubt” about its ability to continue as a going concern.
Redwire Shares Slip After $500 Million Stock Offering Filed

Redwire Shares Slip After $500 Million Stock Offering Filed

9 June 2026
Redwire Corp shares plunged 6.5% to $17.37 after launching a $500 million at-the-market stock program, raising dilution risks for investors as the company seeks flexible funding despite recent record backlog and strong revenue growth; the drop contrasted with gains at other space stocks, highlighting investor concern over potential share issuance.
Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

9 June 2026
Nuvalent shares soared 38.9% to $122.93, just below GSK’s $124-a-share cash offer after the $10.6 billion buyout was announced, as investors bet on the deal closing with Nuvalent’s two lead lung-cancer drugs already under FDA review and a 40% premium to the last closing price driving the morning’s merger-arb trade.
Tesco PLC Tests 24/7 Royal Mail Parcel Lockers at UK Stores as Convenience Race Intensifies
Previous Story

Tesco PLC Tests 24/7 Royal Mail Parcel Lockers at UK Stores as Convenience Race Intensifies

Rentokil Initial plc in Focus as GIC Cuts Stake Days After 2025 Results
Next Story

Rentokil Initial plc in Focus as GIC Cuts Stake Days After 2025 Results

Go toTop